RxDoctor Payments Data

Alipasha Adrangui, MD

Hospitalist · Pasadena, CANPI 1780911263

Payments from drug & device makers

$448in general payments, 2019–2025

Across 10 payments — averaging $44.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$249
  • E.r. Squibb & Sons, L.L.C.$62
  • Smith+Nephew$37
  • Johnson & Johnson$36
  • Pfizer$23
  • Nabriva Therapeutics, PLC$23
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$448100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$448 in reported general payments places this provider in the 80th percentile of 2,469 hospitalist providers in California.

See all hospitalist providers in California

Medicare billing

Part B allowed, 2024
$116,852
Medicare patients
352
Services billed
1,228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban49$23,947
JardianceEmpagliflozin17$17,098
EntrestoSacubitril/Valsartan22$15,470
Levetiracetam13$515
Topiramate11$294
Atorvastatin Calcium26$292
Carvedilol22$247
Levothyroxine Sodium23$205
Amlodipine Besylate38$202
ClopidogrelClopidogrel Bisulfate15$168
Tamsulosin Hcl14$164
Rosuvastatin Calcium14$155
Pantoprazole Sodium13$155
Losartan Potassium17$142
Ciprofloxacin Hcl17$114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$23,94749 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,469 hospitalist providers in California.

Other hospitalist in Pasadena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →